About Ocular Therapeutix, Inc.
https://www.ocutx.comOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
CEO
Pravin U. Dugel
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 121
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Chardan Capital
Buy
Needham
Buy
HC Wainwright & Co.
Buy
TD Cowen
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:31.79M
Value:$351.87M
VR ADVISER, LLC
Shares:13.16M
Value:$145.7M
SUMMER ROAD LLC
Shares:12.58M
Value:$139.26M
Summary
Showing Top 3 of 244
About Ocular Therapeutix, Inc.
https://www.ocutx.comOcular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $14.54M ▲ | $81.47M ▲ | $-69.42M ▼ | -477.3% ▲ | $-0.38 ▲ | $-65.34M ▼ |
| Q2-2025 | $13.46M ▲ | $79.16M ▲ | $-67.81M ▼ | -503.86% ▲ | $-0.39 ▼ | $-63.77M ▼ |
| Q1-2025 | $10.7M ▼ | $73.35M ▲ | $-64.05M ▼ | -598.74% ▼ | $-0.38 ▼ | $-60.09M ▼ |
| Q4-2024 | $17.08M ▲ | $66.43M ▲ | $-48.39M ▼ | -283.27% ▼ | $-0.29 ▼ | $-44.33M ▼ |
| Q3-2024 | $15.43M | $59.86M | $-36.49M | -236.58% | $-0.22 | $-32.31M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $344.77M ▼ | $410.88M ▼ | $152.65M ▲ | $258.23M ▼ |
| Q2-2025 | $391.13M ▲ | $451.33M ▲ | $145.42M ▲ | $305.92M ▲ |
| Q1-2025 | $349.68M ▼ | $405.92M ▼ | $139.99M ▼ | $265.93M ▼ |
| Q4-2024 | $392.1M ▼ | $457.94M ▼ | $142.59M ▲ | $315.34M ▼ |
| Q3-2024 | $427.22M | $490.37M | $138.35M | $352.02M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-69.42M ▼ | $-50.73M ▲ | $-5.99M ▼ | $10.36M ▼ | $-46.36M ▼ | $-56.72M ▼ |
| Q2-2025 | $-67.81M ▼ | $-55.24M ▼ | $-1.11M ▲ | $97.81M ▲ | $41.45M ▲ | $-56.48M ▼ |
| Q1-2025 | $-64.05M ▼ | $-44.67M ▼ | $-1.93M ▼ | $4.18M ▼ | $-42.42M ▼ | $-46.6M ▼ |
| Q4-2024 | $-48.39M ▼ | $-39.43M ▼ | $-202K ▼ | $4.51M ▲ | $-35.12M ▼ | $-39.63M ▼ |
| Q3-2024 | $-36.49M | $-36.56M | $-89K | $4.18M | $-32.47M | $-36.65M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Product | $0 ▲ | $0 ▲ | $10.00M ▲ | $10.00M ▲ |
 Product revenue net | $30.00M ▲ | $10.00M ▼ | $0 ▼ | $0 ▲ |
CEO
Pravin U. Dugel
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 121
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
Chardan Capital
Buy
Needham
Buy
HC Wainwright & Co.
Buy
TD Cowen
Buy
JMP Securities
Market Outperform
Citizens Capital Markets
Market Outperform
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:31.79M
Value:$351.87M
VR ADVISER, LLC
Shares:13.16M
Value:$145.7M
SUMMER ROAD LLC
Shares:12.58M
Value:$139.26M
Summary
Showing Top 3 of 244